F
FOREST HILLS LAB KOREA CO LTD
Forest Hills Lab is engaged in developing anti-aging cosmeceutical products and therapeutic drugs for neurodegenerative diseases like Parkinson's and ...
Country/Area ：South Korea
Company Email ：info@foresthillslab.com
Industry ：RetailDrug Stores & Pharmacies
Company address ：Hong Kong, China
Company website ：*****
Company phone ：+852 21550487
Established ：2018
Company Revenue ：$2,521,000
Number of employees ：<25
SIC Code ：51512
NAICS Code ：42424
Main Products ：Neuro-MedForest Hills Lab
Company News
Forest Hills Lab Expands Pipeline and Readies for Clinical Development
Aug 22, 2022
HONG KONG, S.A.R., August 22, 2022 /EINPresswire.com/ -- Forest Hills Lab (FHL) is an innovative regenerative medicine company seeking to improve the quality of life of our rapidly aging society. FHL’s Neuro-Med division, which is a therapeutic drug …
Aug 22, 2022
Forest Hills Lab Announces Additions to Cos-Med Division’s Leadership TeamMay 10, 2022
Ella Fong joining as Chief Commercial Officer, Ik-Hwan Cho as CEO of NewMedic subsidiary HONG KONG, May 10, 2022 /EINPresswire.com/ -- Forest Hills Lab (FHL) is an innovative regenerative medicine company seeking to improve the quality of life of our …
May 10, 2022FHL Announces Phase 2 Clinical Trial for Parkinson’s Drug, Korean Medical Device Company Acquisition and Saudi JVJul 20, 2021
HONG KONG, CHINA, July 20, 2021 /EINPresswire.com/ -- Forest Hills Partners Hong Kong Ltd. (Forest Hills Lab or FHL) management announced today an important FDA approval for a Phase 2 clinical trial to develop a drug for Parkinson’s and the signing of …
Jul 20, 2021Forest Hills Lab is filing an IND to initiate a clinical phase 2 study on Parkinson's disease with the US FDAMar 24, 2021
HONG KONG, March 23, 2021 /PRNewswire/ -- Forest Hills Partners Hong Kong Limited (also known as Forest Hills Lab) is ready to file an Investigative New Drug (IND) application with the US FDA in April 2021 to assess tolerability and efficacy with one of its drug candidates, namely FHL-301 in a phase 2 clinical study for patients diagnosed with Parkinson's disease. Parkinson's disease (PD) is one of the most prevalent neurodegenerative disorders among aging population
Mar 24, 2021Safety and excellent Korea HA filler provided by Forest Hills Lab at Cosmoprof of Asia Digital Week - Scheduled to obtain CE in July 2021Feb 9, 2021
HONG KONG, Feb. 9, 2021 /PRNewswire/ -- Xspurt will be launched by Forest Hills Lab at Cosmoprof Asia Digital Week and scheduled to obtain CE in July 2021. Xspurt is non-animal based, crosslinked dermal filler using BDDE for linking agent. Xsputy product is obtained through their unique...
Feb 9, 2021Web Summary
Q1: What is the company name and its main focus?
A1: The company name is Forest Hills Lab Korea Co. Ltd, and its main focus is on regeneration and improving well-being in a rapidly aging society.
Q2: Where are the company's global offices located?
A2: The company has offices in the United States, Singapore, South Korea, and Hong Kong, with its headquarters in Hong Kong.
Q3: What are the two divisions of Forest Hills Lab Korea Co. Ltd?
A3: The company is composed of two divisions: FHL Therapeutics and FHL Aesthetics.
Q4: What products does FHL Aesthetics develop and market globally?
A4: FHL Aesthetics develops and markets a comprehensive line of medical- and non-medical-grade aesthetics products globally, with Korean R&D and manufacturing excellence.
Q5: What is the controlling shareholder of Forest Hills Lab Korea Co. Ltd?
A5: The company's controlling shareholder is Mstone Healthcare Partners, an entrepreneurial incubator building aesthetics and healthcare, life sciences, and AI-related companies.
Q6: How can one contact Forest Hills Lab Korea Co. Ltd for inquiries or business purposes?
A6: One can contact the company through its email address (info@foresthillslab.com) or phone number (+852 2155 0487).
Q7: What is the purpose of Mstone Platform and Mstone Healthcare Partners?
A7: Mstone Platform and Mstone Healthcare Partners are part of Forest Hills Lab Korea Co. Ltd, with Mstone founds, staffs, develops, and grows portfolio companies by building upon novel technology as well as human and investment capital.
Q8: What is the current status of FHL Therapeutics' pipeline?
A8: FHL Therapeutics has a clinical stage biopharmaceutical advancing a multi-modal pipeline of seven potentially disease-modifying neurological assets, initially targeting Alzheimer’s and Parkinson’s disease.
A1: The company name is Forest Hills Lab Korea Co. Ltd, and its main focus is on regeneration and improving well-being in a rapidly aging society.
Q2: Where are the company's global offices located?
A2: The company has offices in the United States, Singapore, South Korea, and Hong Kong, with its headquarters in Hong Kong.
Q3: What are the two divisions of Forest Hills Lab Korea Co. Ltd?
A3: The company is composed of two divisions: FHL Therapeutics and FHL Aesthetics.
Q4: What products does FHL Aesthetics develop and market globally?
A4: FHL Aesthetics develops and markets a comprehensive line of medical- and non-medical-grade aesthetics products globally, with Korean R&D and manufacturing excellence.
Q5: What is the controlling shareholder of Forest Hills Lab Korea Co. Ltd?
A5: The company's controlling shareholder is Mstone Healthcare Partners, an entrepreneurial incubator building aesthetics and healthcare, life sciences, and AI-related companies.
Q6: How can one contact Forest Hills Lab Korea Co. Ltd for inquiries or business purposes?
A6: One can contact the company through its email address (info@foresthillslab.com) or phone number (+852 2155 0487).
Q7: What is the purpose of Mstone Platform and Mstone Healthcare Partners?
A7: Mstone Platform and Mstone Healthcare Partners are part of Forest Hills Lab Korea Co. Ltd, with Mstone founds, staffs, develops, and grows portfolio companies by building upon novel technology as well as human and investment capital.
Q8: What is the current status of FHL Therapeutics' pipeline?
A8: FHL Therapeutics has a clinical stage biopharmaceutical advancing a multi-modal pipeline of seven potentially disease-modifying neurological assets, initially targeting Alzheimer’s and Parkinson’s disease.
Customs Data
As a purchaser
As a Supplier
Get the Whole details
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Get the Whole details
